HRTX Jumps About +31% in Snapshot as CorMedix Asset Deal Reshapes Heron’s Future
Heron’s proposed asset sale brings cash and CorMedix shares, but closing conditions, debt and its next business strategy remain central for HRTX holders.
Read the story
Heron’s proposed asset sale brings cash and CorMedix shares, but closing conditions, debt and its next business strategy remain central for HRTX holders.
Read the story